A Phase 2 interventional study of Psilocybin in Alcohol Use Disorder and Alcoholism, sponsored by University of Calgary. Recruiting at 1 site in Canada. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-05-07.
Sponsored by University of Calgary · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing psilocybin in Alcoholism — 8 open to participants now, 13 under way, 1 of them phase 3. Psilocybin · Alcoholism.
Among the 17 studies testing psilocybin in Alcoholism, this one is the 3rd largest by planned enrollment, is one of 4 that started in 2024, is one of 16 in phase 2, reaches primary completion later than 7 of the 12 other live ones, and was the 9th registered.
1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.
Browse Alcoholism studies →8 of the 17 studies testing psilocybin in Alcoholism are open now, in 4 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18–65
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–65
University of Iowa · Sites in United States
Ages 21–65
Brugmann University Hospital · Sites in Belgium
Ages 21–64
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 22 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2024.
This study's planned enrollment of 128 is above the median of 88 across 1,433 interventional studies indexed under Alcoholism.
Median enrollment 62 across the 17 interventional studies. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 17 have an industry lead sponsor. The 10 most frequent:
University of Calgary is the lead sponsor of 704 studies on the registry; 197 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 2 (20%) have results posted.
University of Calgary has 1 study filed under Alcoholism — fewer than ten, so there is no comparison to draw.
1 of the studies testing psilocybin in Alcoholism that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05995769University of CalgaryPsilocybin-Assisted Psychotherapy for Alcohol Use Disorder | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing psilocybin in Alcoholism, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to determine if a single dose of psilocybin administered with motivational enhancement therapy (MET) can reduce heavy drinking in patients with an alcohol use disorder (AUD).
The primary objective of this study is to determine if psilocybin administered with a standardized psychotherapeutic intervention, motivational enhancement therapy (MET), can reduce heavy drinking in a patient population with an alcohol use disorder (AUD). Patients with an AUD will be randomly allocated to either a high dose (25mg; active treatment) or a low dose (1mg; active control) psilocybin arm. All participants will receive 5 sessions of MET, starting at 24hrs post-dosing. Heavy drinking will be assessed as percent heavy drinking days using the Time Line Follow Back (TLFB) at baseline and 1-, 4-, and 12-weeks post-dosing.
A total of 128 male and female patients between the ages of 22-65 with a moderate to severe AUD diagnosis will be recruited from the community. Participants will undergo a thorough screening procedure and eligible participants will be randomly allocated to the high (N=64) or low (N=64) psilocybin doses. All participants will complete a baseline session consisting of clinical, behavioral, and neuroimaging measures. Following the single dosing session, participants will complete 5 weekly MET sessions. Neuroimaging measures will be assessed again at 1-week post-doing. Clinical and behavioral outcomes will be measured at 1-, 4-, and 12-weeks post-dosing
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PEX010 (Oral Psilocybin), 25mg; single dose administered 24hrs prior to first of 5 weekly MET sessions
Drug: Psilocybin
PEX010 (Oral Psilocybin), 1mg; single dose administered 24hrs prior to first of 5 weekly MET sessions
Drug: Psilocybin
Single dosing session followed by 5 MET weekly sessions starting 24hrs after dosing
Also known as: magic mushrooms, PEX010
Heavy drinking
Percent heavy drinking days (TLFB)
Time frame: Change from baseline to 1-, 4-, and 12-weeks post-dosing
Abstinence
Days abstinent (TLFB)
Time frame: Change from baseline to 1-, 4-, and 12-weeks post-dosing
Biomarkers of alcohol consumption
Phosphatidylethanol (Peth)
Time frame: Change from baseline to 1-, 4-, and 12-weeks post-dosing
Alcohol cue reactivity
Alcohol urge questionnaire (AUQ)
Time frame: Change from baseline to 1-, 4-, and 12-weeks post-dosing
Cognitive flexibility
Berg Card Sorting Task
Time frame: Change from baseline to 1-, 4-, and 12-weeks post-dosing
Depression
The Montgomery-Åsberg Depression Rating Scale (MADRS)
Time frame: Change from baseline to 1-, 4-, and 12-weeks post-dosing
Anxiety
The General Anxiety Disorder 7 (GAD-7) scale
Time frame: Change from baseline to 1-, 4-, and 12-weeks post-dosing
Quality of life
The World Health Organization Quality of Life (WHOQOL) scale
Time frame: Change from baseline to 1-, 4-, and 12-weeks post-dosing
Glutamate levels
MR spectroscopy of glutamate levels in the anterior cingulate cortex
Time frame: Change from baseline to 1-week post-dosing
GABA levels
MR spectroscopy of GABA levels in the anterior cingulate cortex
Time frame: Change from baseline to 1-week post-dosing
Resting state functional connectivity
Time frame: Change from baseline to 1-week post-dosing
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Oct 2027, 42 months after the start.
Of 123 non-industry phase 2 interventional studies under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 42 months is above that.
Counting every sponsor, half of 135 studies reached it within 33 months; a quarter within 21 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Psilocybin